Sonoma Pharmaceuticals (STU:O8Z3) Total Stockholders Equity : €6.14 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Sonoma Pharmaceuticals Total Stockholders Equity?

Sonoma Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €6.14 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Sonoma Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was €0.45. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Sonoma Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.06.

Sonoma Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Sonoma Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals Total Stockholders Equity Chart

Sonoma Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Stockholders Equity

Get a 7-Day Free Trial

9.28

5.09

4.51

7.90

7.45

Sonoma Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															5.25	7.45	6.68	5.32	6.14

Sonoma Pharmaceuticals (STU:O8Z3) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Sonoma Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(6.137	-	0)	/	13.6843
	=	0.45

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Sonoma Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.206	+	0.147)	/	6.137
	=	0.06

Sonoma Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sonoma Pharmaceuticals (STU:O8Z3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (STU:O8Z3) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

SNOA:USA

Address

5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301

Website

https://www.sonomapharma.com

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.

Sonoma Pharmaceuticals (STU:O8Z3) Headlines

No Headlines